Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Denise K. Oseguera"'
Autor:
Jesus Gomez-Navarro, James S. Economou, Ena Wang, Francesco M. Marincola, Liu Hui, John A. Glaspy, Alistair J. Cochran, Bradley R. Straatsma, Denise K. Oseguera, Arturo Villanueva, Elizabeth Seja, Maria Teresa Ochoa, Tara A. McCannel, Pilar de la Rocha, Jason Jalil, Bartosz Chmielowski, Begoña Comin-Anduix, Antoni Ribas
Supplementary Table S1 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c775c5786b020ca538cdf9317cff78e
https://doi.org/10.1158/1078-0432.22439974.v1
https://doi.org/10.1158/1078-0432.22439974.v1
Autor:
Jesus Gomez-Navarro, James S. Economou, Ena Wang, Francesco M. Marincola, Liu Hui, John A. Glaspy, Alistair J. Cochran, Bradley R. Straatsma, Denise K. Oseguera, Arturo Villanueva, Elizabeth Seja, Maria Teresa Ochoa, Tara A. McCannel, Pilar de la Rocha, Jason Jalil, Bartosz Chmielowski, Begoña Comin-Anduix, Antoni Ribas
Supplementary Table S2 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350b101aee753a1130888f1ac6e921b7
https://doi.org/10.1158/1078-0432.22439971
https://doi.org/10.1158/1078-0432.22439971
Autor:
Jesus Gomez-Navarro, James S. Economou, Ena Wang, Francesco M. Marincola, Liu Hui, John A. Glaspy, Alistair J. Cochran, Bradley R. Straatsma, Denise K. Oseguera, Arturo Villanueva, Elizabeth Seja, Maria Teresa Ochoa, Tara A. McCannel, Pilar de la Rocha, Jason Jalil, Bartosz Chmielowski, Begoña Comin-Anduix, Antoni Ribas
Purpose: Tumor antigen–loaded dendritic cells (DC) are believed to activate antitumor immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)–blocking antibodies should release a key negative regulatory pathway on T cells. The combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::571beeec5ed7803a0b00b4530f69968b
https://doi.org/10.1158/1078-0432.c.6517354.v1
https://doi.org/10.1158/1078-0432.c.6517354.v1
Autor:
Vina P. Nguyen, John A. Glaspy, Anthony T. Nguyen, Deborah J. Wong, Maggie L. DiNome, Denise K. Oseguera, Stephen L. Shiao, Helena R. Chang
Publikováno v:
Cancer Research. 81:OT-13
Background: Immunotherapy has emerged as a novel therapeutic strategy in many solid malignancies. In breast cancer, treatment with checkpoint inhibitors alone showed minimal response rates, likely because breast cancers are not sufficiently immunogen
Autor:
Pilar de la Rocha, Begoña Comin-Anduix, Elizabeth Seja, Arturo Villanueva, Francesco M. Marincola, John A. Glaspy, Jason Jalil, Ena Wang, Alistair J. Cochran, Antoni Ribas, Tara A. McCannel, Jesus Gomez-Navarro, Maria Teresa Ochoa, Bradley R. Straatsma, Denise K. Oseguera, Liu Hui, James S. Economou, Bartosz Chmielowski
Publikováno v:
Clinical Cancer Research. 15:6267-6276
Purpose: Tumor antigen–loaded dendritic cells (DC) are believed to activate antitumor immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)–blocking antibodies should release a key negative regulatory pathway on T cells. The combi
Autor:
Lazar Vujanovic, Denise K. Oseguera, Elizabeth Seja, Hong T. Vu, Douglas M. Potter, Antoni Ribas, Begonya Comin-Anduix, Vivian B. Dissette, John A. Glaspy, Lisa H. Butterfield, James S. Economou, Yohan Lee, Jin-Quan Yang
Publikováno v:
Journal of Immunotherapy. 31:294-309
Dendritic cells (DCs) are the key physiologic stimulators of naive and primed cells to an antigen.1,2 Many types of myeloid DCs have been tested clinically with objective clinical responses, both partial and complete. Many current immunotherapy effor
Autor:
Huong T. Vu, Elisabeth Seja, Denise K. Oseguera, Saral N. Amarnani, William H. McBride, N. Simon Tchekmedyian, Yohan Lee, Vivian B. Dissette, Antoni Ribas, James S. Economou, Lisa H. Butterfield, Begonya Comin-Anduix, John A. Glaspy, Jennifer A. Wargo
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 27(5)
MART-1(27-35)-peptide-pulsed immature dendritic cells (DCs) resulted in immunologic and clinical activity in a prior phase 1 trial. A phase 2 cohort expansion was initiated to further characterize the phenotype and cytokine milieu of the DC vaccines
Autor:
Sun Min Lee, Luis H. Camacho, Charles K. Brown, J. Hernandez, Peggie Mitsky, Jon M. Richards, Didier Landais, Maria Jovie Rodriguez, Evan M. Hersh, John A. Glaspy, Nadège Bercovici, Denise K. Oseguera, Bartosz Chmielowski, Victor G. Prieto, Arturo Villanueva, Antoni Ribas, Merrick I. Ross, Ernesto Wasserman
Publikováno v:
Journal of Translational Medicine
Ribas, Antoni; Camacho, Luis H; Lee, Sun; Hersh, Evan M; Brown, Charles K; Richards, Jon M; et al.(2010). Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of Translational Medicine, 8(1), 89. doi: http://dx.doi.org/10.1186/1479-5876-8-89. Retrieved from: http://www.escholarship.org/uc/item/994851m0
Journal of Translational Medicine, Vol 8, Iss 1, p 89 (2010)
Ribas, Antoni; Camacho, Luis H; Lee, Sun; Hersh, Evan M; Brown, Charles K; Richards, Jon M; et al.(2010). Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of Translational Medicine, 8(1), 89. doi: http://dx.doi.org/10.1186/1479-5876-8-89. Retrieved from: http://www.escholarship.org/uc/item/994851m0
Journal of Translational Medicine, Vol 8, Iss 1, p 89 (2010)
Background Several single center studies have provided evidence of immune activation and antitumor activity of therapeutic vaccination with dendritic cells (DC) in patients with metastatic melanoma. The efficacy of this approach in patients with favo